Factor VIII Antikörper

Produktnummer ABIN111959

Der Maus Monoklonal anti-Factor VIII Antikörper wird verwendet zum Nachweis von Factor VIII in Proben von Human. Er wurde validiert für EIA.

Kurzübersicht für Factor VIII Antikörper (ABIN111959)

Target: Factor VIII (F8) (Coagulation Factor VIII (F8))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Factor VIII Antikörper ist unkonjugiert

Applikation: Enzyme Immunoassay (EIA)

Klon: 2A5

Produktdetails anti-Factor VIII Antikörper

Spezifität: This antibody recognizes the 83 kDa light chain of Factor VIII. It does not cross-react with Von Willebrand factor.

Aufreinigung: Affinity Chromatography on Protein A

Immunogen: Purified Human Factor VIII

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: ELISA. Functional assays.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: PBS, pH 7.2 containing 0.09 % Sodium Azide as preservative

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Details zu Factor VIII

Target: Factor VIII (F8) (Coagulation Factor VIII (F8))

Hintergrund: Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50 % of patients have severe hemophilia A with F8C activity less than 1 % of normal, they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10 % of patients, F8C activity is 2-5 % of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40 % of patients, is associated with F8C activity of 5-30 % and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5 %) that have considerable amount of F8C in their plasma (at least 30 % of normal), but the protein is nonfunctional, i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.Synonyms: AHF, Antihemophilic factor, F8C, Procoagulant component

Gen-ID: 2157

NCBI Accession: NP_000123

UniProt: P00451